Journal of Controlled Release Submission Guide

Source: Clarivate JCR 2024, Elsevier editorial disclosures (accessed April 2026).

Source: Journal of Controlled Release author guidelines.

Use this page when deciding:

• whether the delivery-mechanism contribution is substantive

• whether in-vivo validation is included

• whether translational relevance is direct

• a clear drug-delivery mechanism contribution

• in-vivo validation appropriate to the application

• direct translational relevance

• rigorous methodology with characterization and pharmacokinetics

• a cover letter establishing the delivery contribution

• Incremental formulation reports without delivery mechanism.

• Missing in-vivo validation.

• Weak translational framing.

• Drug discovery without delivery focus.

Journal of Controlled Release is a flagship drug-delivery research journal.

Mechanism + translational standard: the journal differentiates from International Journal of Pharmaceutics (broader) and Drug Delivery (broader applied) by demanding both delivery mechanism and translational relevance.

In-vivo expectation: editors expect animal or in-vivo data on systems framed for therapeutic use.

The 40-50% desk rejection rate: decisive editorial screen.

The strongest Journal of Controlled Release cover letters establish:

• the delivery-mechanism contribution

• the in-vivo validation

• the translational relevance

• the central finding

For Journal of Controlled Release submissions, the editorial timeline runs through four phases. Published data indicates acceptance runs 20-25% with desk-rejection around 40-50%; the journal's two-stage formatting requirement shifts work toward the revision stage rather than the initial submission.

Day 0 to 5: Editorial Manager intake and editor assignment

Elsevier intake handles format compliance plus the AI-declaration and ethics-statement checks. The handling Editor assignment lands within 5 days; drug-delivery papers route to subject editors matching the delivery subfield (nanoparticles, hydrogels, sustained-release implants, oral delivery, vaccine delivery). The most common Day 0-5 hold-up: missing in vivo validation context in the cover letter.

Day 5 to 21: Editor scope and translational screen

Journal of Controlled Release's editor filter prioritizes delivery-mechanism contributions backed by in vivo translational evidence. The most common Day 5-21 desk reject in our review work: incremental formulation reports without rigorous mechanism analysis, missing in vivo validation, weak translational framing, or scope mismatch where the contribution is drug discovery rather than delivery. Roughly 40-50% of submissions exit at this stage via desk rejection.

Week 3 to 10: Peer review

Standard 2-3 reviewers, 4-8 week first decision target. Reviewer mix typically includes one formulation-science expert plus one in vivo or translational specialist. Submissions missing comparator-formulation benchmarks, dose-response analysis, or release-kinetics characterization extend reviewer dialogue by 3-5 weeks.

Week 10 to 24: Decision, revision, and formatting

Major revision is the standard first decision at Journal of Controlled Release. At the revision stage, authors must reformat to the strict journal style (this is when the structured submission requirements kick in). Revision rounds typically settle at 2 (rarely 3 for accepted papers). Total submission-to-acceptance: 5-8 months for accepted papers.

• Is Journal of Controlled Release a good journal?

• Advanced Drug Delivery Reviews submission guide

Before upload, run your manuscript through a Journal of Controlled Release mechanism and translational readiness check.

Use the guide for portal, routing, and policy details; use the manuscript check for the editor-facing fit call. The review tells you whether your paper clears the Journal of Controlled Release fit check before upload, especially around formulation manuscript where controlled release is a performance label, therapeutic claim without in-vivo or biologically anchored evidence, and nanomaterials or polymer chemistry story with delivery added late. Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.

Across drug-delivery manuscripts targeting Journal of Controlled Release, three submission shapes reliably predict desk-screen failure. The journal's Elsevier guide explains the upload package, but the editorial fit turns on whether the manuscript components prove controlled release as the scientific contribution rather than treating delivery as an application label.

Formulation manuscript where controlled release is a performance label

Across Journal of Controlled Release manuscripts, a common failure mode is a formulation paper whose abstract says controlled release but whose figures prove only particle size, loading efficiency, encapsulation, morphology, and short in-vitro release. JCR editors need a delivery mechanism: how the carrier, matrix, polymer, hydrogel, depot, nanoparticle, device, or conjugate controls release under relevant biological or application conditions.

The methods should make the release assay credible, including medium, sink conditions, sampling schedule, analytical method, model fit, replicate structure, and stability controls. The figures should connect release behavior to a mechanistic design choice rather than reporting one more optimized formulation. A cover letter that only says the system improves drug delivery is usually too generic.

Stronger packages explain why the mechanism belongs in Journal of Controlled Release rather than International Journal of Pharmaceutics, Biomaterials, Acta Biomaterialia, Molecular Pharmaceutics, or Advanced Drug Delivery Reviews. If the manuscript cannot name the release-control decision, it reads like formulation screening, not a JCR contribution.

Check formulation manuscript where controlled release is a performance label before submitting to Journal of Controlled Release →

Therapeutic claim without in-vivo or biologically anchored evidence

The second pattern is an evidence ladder that stops too early. Across Manusights submission reviews, Journal of Controlled Release manuscripts often make therapeutic, targeting, toxicity-reduction, pharmacokinetic, or biodistribution claims from cell assays and release curves alone. That is usually too thin for a high-level controlled-release submission. The abstract and cover letter should keep the claim proportional to the actual manuscript components.

If the figures describe tumor targeting, immune delivery, brain delivery, local depot therapy, oral bioavailability, or sustained exposure, the methods and supplementary files need in-vivo, ex-vivo, organoid, tissue, pharmacokinetic, biodistribution, safety, or clinically relevant model evidence. For purely in-vitro systems, the manuscript must be disciplined about mechanism and avoid therapeutic language that the evidence does not support.

Editors and reviewers notice when release data, animal design, dose selection, controls, and statistics are not aligned. The fix is either to add the missing biological evidence or to retarget the manuscript to a formulation, polymer, materials, or analytical venue where the evidence ladder is appropriate.

Check therapeutic claim without in vivo or biologically anchored evidence before submitting to Journal of Controlled Release →

Nanomaterials or polymer chemistry story with delivery added late

The third recurring pattern is a manuscript whose real contribution is materials chemistry, nanoparticle synthesis, surface functionalization, or polymer architecture, while controlled release appears mostly in the final experiment. Journal of Controlled Release can publish materials-led work, but the delivery problem has to be central from title through discussion.

The abstract should define the delivery barrier, the figures should show how the design changes release or localization, the methods should support release quantification and biological context, and the cover letter should explain the translational relevance without overstating clinical proximity.

If the most natural readership is Biomaterials, ACS Applied Materials & Interfaces, Molecular Pharmaceutics, Advanced Healthcare Materials, or a cancer nanotechnology venue, JCR may not be the cleanest first target. In Manusights reviews, the strongest JCR submissions make the delivery mechanism, release data, biological validation, and translational boundary visible before reviewers reach the supplementary information.

A Journal of Controlled Release mechanism and translational readiness check can identify whether the package supports a submission.

Clarivate JCR 2024 bibliometric data places Journal of Controlled Release among top drug-delivery journals.

Check nanomaterials or polymer chemistry story with delivery added late before submitting to Journal of Controlled Release →

In pre-submission diagnostic work for top drug-delivery journals, we consistently see four signals that distinguish strong submissions from weak ones. First, the contribution must be mechanism-focused, not formulation-only. Second, in-vivo validation should accompany any therapeutic claim. Third, translational relevance should be direct. Fourth, methodology should include rigorous characterization and pharmacokinetic analysis.

For Journal Of Controlled Release-targeted manuscripts, the single most consistent feedback class we deliver in pre-submission diagnostics for Journal of Controlled Release is the formulation-versus-mechanism distinction. Journal of Controlled Release editors expect mechanistic understanding of drug release. Submissions framed as "we developed nanoparticle formulation X with property Y" routinely receive "what is the delivery mechanism?" feedback during desk screening.

We coach authors to lead with the delivery-mechanism question and frame the formulation work in service of that question. Papers framed as "we elucidated how mechanism X drives controlled release behavior Y in delivery system Z, validated in vivo with pharmacokinetic analysis" receive better editorial traction.

The same logic applies across drug-delivery journals: editors are operating with limited slot inventory, and the submissions that get traction lead with the mechanism question.

For Journal Of Controlled Release-targeted manuscripts, beyond the rubric checks, three pre-submission diagnostic patterns recur most often in the manuscripts we review for Journal of Controlled Release. First, manuscripts where the abstract reports formulation properties without delivery mechanism are flagged at desk for incremental framing. We recommend the abstract's central sentences state the delivery question, the mechanism, and the translational finding.

Second, manuscripts where in-vivo data is reported only in supplementary materials rather than as central evidence are flagged for translational framing gaps. We recommend integrating in-vivo data into main figures. Third, manuscripts that lack engagement with Journal of Controlled Release's recent issues are at risk of being told the contribution doesn't fit the publication conversation.

For Journal Of Controlled Release-targeted manuscripts, the strongest manuscripts we coach distinguish themselves on three operational behaviors. First, they confine the cover letter to one page and use it to make the case for fit, contribution, and significance, not to summarize the abstract. Second, they include a one-sentence elevator pitch in the cover letter's opening that the editor can use when discussing the manuscript internally.

Third, they identify the specific recent papers in the journal that this manuscript builds on and the specific competing or contradicting work; this signals the authors are operating inside the publication conversation rather than outside it.